Beijing-based PhenoVision Biotech, a one-stop spatial multi-omics solution provider, has reportedly secured “tens of millions” of renminbi in an angel financing round led exclusively by SIP Oriza Seed Fund. The proceeds will be dedicated to constructing a spatial multi-omics technology platform and advancing the development of clinical products.
Funding and Utilization
The funds raised will primarily support the development of PhenoVision’s spatial multi-omics technology platform, which integrates spatial proteomics, spatial transcriptomics, and single-cell sequencing technologies. These advancements are crucial for translating research on complex diseases such as neurological disorders, tumors, and developmental conditions into clinical applications.
Technological Innovation
PhenoVision is pioneering the development of a unique solution in China that can simultaneously capture multi-omics (DNA, RNA, protein) spatial information within a single device. This innovation combines global licensing and in-house research, positioning PhenoVision at the forefront of precision clinical pathology solutions.-Fineline Info & Tech
